LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Kodu・Aktsiate loetelu・Gilead Sciences Inc.

Gilead Sciences Inc.

Suletud

SektorTervishoid

129.48 0.26

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

128.92

Max

130.03

Põhinäitajad
By Trading Economics
Sissetulek	-162M 2B
Müük	-965M 7B
P/E Sektori keskmine	17.837 49.888
Aktsiakasum	2.03
Dividenditootlus	2.37
Kasumimarginaal	29.037
Töötajad	17,000
EBITDA	1.2B 3.5B

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+23.96% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	2.37% 2.38%
Järgmine tulemuste avaldamine	6. aug 2026
Järgmine dividendimakse kuupäev	29. juuni 2026
Järgmine aktsia dividendi kuupäev (ex-date)	15. juuni 2026

Turustatistika
By TradingEconomics
Turukapital	-1.9B 163B
Eelmine avamishind	129.22
Eelmine sulgemishind	129.48

Uudiste sentiment

By Acuity

18%

82%

22 / 344 Pingereas Healthcare

Gilead Sciences Inc. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. mai 2026, 20:49 UTC

Tulu

Gilead Sciences Expects Loss This Year on Acquired R&D Expenses

7. apr 2026, 14:24 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion -- Update

7. apr 2026, 12:53 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion

4. juuni 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

8. mai 2026, 08:10 UTC

Tulu

Gilead Stock Falls After Earnings. A Big Acquisition Spree Is Coming at a Cost. -- Barrons.com

8. mai 2026, 08:08 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7. mai 2026, 22:33 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7. mai 2026, 21:09 UTC

Tulu

Gilead Earnings Show HIV Drugs Continue to Shine. Why the Guidance Cut? -- Barrons.com

7. mai 2026, 20:51 UTC

Tulu

Gilead Earnings Show HIV Drugs Continue to Shine. Why the Guidance Cut? -- Barrons.com

7. mai 2026, 20:06 UTC

Tulu

Gilead Sciences Raises 2026 View To Sales $30B-$30.4B >GILD

7. mai 2026, 20:05 UTC

Tulu

Gilead Sciences Sees 2026 Adj Loss/Shr 65c-Adj Loss/Shr $1.05 >GILD

7. mai 2026, 20:05 UTC

Tulu

Gilead Sciences Sees 2026 Loss/Shr $2.85-Loss $3.25 >GILD

7. mai 2026, 20:02 UTC

Tulu

Gilead Sciences: Biktarvy Sales Increased 7% Yr-Over-Yr to $3.4B >GILD

7. mai 2026, 20:01 UTC

Tulu

Gilead Sciences 1Q Rev $6.96B >GILD

7. mai 2026, 20:01 UTC

Tulu

Gilead Sciences 1Q Adj EPS $2.03 >GILD

7. mai 2026, 20:01 UTC

Tulu

Gilead Sciences 1Q Total Liver Disease Sales $767M >GILD

7. mai 2026, 20:01 UTC

Tulu

Gilead Sciences 1Q EPS $1.61 >GILD

28. apr 2026, 12:45 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences Completes Acquisition Of Arcellx Ahead Of Potential Commercial Launch Of Anito-cel >GILD

17. apr 2026, 12:32 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences Extends Arcellx Tender Offer >GILD ACLX

17. apr 2026, 12:30 UTC

Omandamised, ülevõtmised, äriostud

Gilead Receives All Required Regulatory Approvals For The Acquisition Of Arcellx And Extends Tender Offer >GILD

7. apr 2026, 14:36 UTC

Omandamised, ülevõtmised, äriostud

EQT Life Sciences: The Deal Is Expected to Close in 2Q of 2026

7. apr 2026, 14:35 UTC

Omandamised, ülevõtmised, äriostud

EQT Life Sciences: Gilead Plans to Finance Transaction With Cash and Senior Unsecured Notes

7. apr 2026, 14:34 UTC

Omandamised, ülevõtmised, äriostud

EQT Life Sciences: Gilead Will Also Buy TUB-030

7. apr 2026, 14:28 UTC

Omandamised, ülevõtmised, äriostud

EQT Life Sciences to Exit Minority Stake in Tubulis via Sale to Gilead Sciences for Up to $5B

7. apr 2026, 14:23 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Gilead Buying Another Cancer-Drug Partner -- Market Talk

7. apr 2026, 13:55 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Gilead Continues Buying Spree with Tubulis Deal -- Market Talk

7. apr 2026, 13:14 UTC

Omandamised, ülevõtmised, äriostud

Gilead Adds to Cancer Pipeline With Acquisition Worth Up to $5 Billion -- Barrons.com

7. apr 2026, 12:30 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences to Finance Tubulis Deal With Cash on Hand, Senior Unsecured Notes >GILD

7. apr 2026, 12:30 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Tubulis Deal Antibody-Drug Conjugates on Oncology Pipeline >GILD

7. apr 2026, 12:30 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Tubulis Deal Includes Up to $1.85 Billion Contingent Milestone Payments >GILD

Võrdlus sarnastega

Hinnamuutus

Gilead Sciences Inc. Prognoos

Hinnasiht

By TipRanks

23.96% tõus

12 kuu keskmine prognoos

Keskmine 160.11 USD 23.96%

Kõrge 180 USD

Madal 122 USD

Põhineb 21 Wall Streeti analüütiku instrumendi Gilead Sciences Inc. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

21 ratings

Osta

Hoia

Müü

Põhineb 21 analüütiku instrumendi Gilead Sciences Inc. aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

22 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.